News >

Trastuzumab Biosimilar Demonstrates Equivalence in HER2+ Breast Cancer

Jason Harris
Published: Tuesday, Jan 30, 2018

breast cancer
SB3, a trastuzumab (Herceptin) biosimilar developed by Merck and Samsung Bioepsis, induced a rate of breast pathologic complete response (bpCR) similar to trastuzumab in women with HER2-positive breast cancer, according to results from a phase III study of 800 patients.

In December 2017, the FDA approved another trastuzumab biosimilar, MYL-1401O (Ogivri; trastuzumab-dkst), for HER2-positive patients with breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.
Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2–positive early breast cancer [published online January 26, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.74.0126.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication
x